No credit card. No commitment.
5000+ G2 reviews
ElyssaMed SAS
Research
Founded in 2015
Paris, Île-de-France
elyssamed.comElyssaMed SAS
ResearchFounded in 2015Paris, Île-de-France
TechnologiesElyssaMed SAS' financial review
Employees
2
ElyssaMed SAS information
ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and ...
ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.
ElyssaMed SAS industries
Research
Biotechnology research
ElyssaMed SAS' financial review
Employees
2
Technologies
Employees
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download Extension
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Erik Straub
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Michael Transon
CEO, Victorious
